How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) issued its quarterly earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.11. The firm had revenue of $77.90 million for the quarter, compared to the consensus estimate of $72.67 million. During the same quarter in the previous year, the company posted ($0.75) earnings per share.

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE) , Pfizer (PFE) , Amarin (AMRN) , Inovio Pharmaceuticals (INO) , Coty (COTY) , Gilead Sciences (GILD) , Micron Technology (MU) , VBI Vaccines (VBIV) , NVIDIA (NVDA) and Carnival Co. & (CCL) .

When did Myovant Sciences IPO?

Myovant Sciences (MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

NYSE:MYOV

Myovant Sciences (MYOV) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free MYOV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $26.98
▼
$27.00
50-Day Range: $26.88
▼
$26.99
52-Week Range: $7.67
▼
$27.06

Volume: 2.26 million shs
Average Volume: 1.17 million shs
Market Capitalization: $2.62 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Myovant Sciences alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Myovant Sciences Stock (NYSE:MYOV)

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MYOV Stock News Headlines

April 18, 2024 | uk.finance.yahoo.com

World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs

January 15, 2024 | forbes.com

2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout Year

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 11, 2024 | finance.yahoo.com

Global $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and Region

January 3, 2024 | finance.yahoo.com

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

December 28, 2023 | dailymail.co.uk

Vivek Ramaswamy wins legal battle over bid to force him to give evidence in multi-million dollar court case after GOP long-shot candidate claimed he was too busy campaigning to ...

December 8, 2023 | finance.yahoo.com

Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsight

November 21, 2023 | markets.businessinsider.com

NCCN Announces Funding for Advanced Prostate Cancer Research Projects

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

October 22, 2023 | barrons.com

Myovant Sciences, Ltd. (MYOV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

September 26, 2023 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

September 12, 2023 | marketwatch.com

4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business Chief

August 29, 2023 | msn.com

Vivek Ramaswamy claims he is too busy campaigning to give evidence

August 29, 2023 | msn.com

2024 Presidential candidate Vivek Ramaswamy trying to duck legal battle over his biotech empire

August 28, 2023 | msn.com

EXCLUSIVE: Vivek Ramaswamy claims he is too busy campaigning for President to give evidence in multi-million dollar court case

August 28, 2023 | msn.com

Vivek Ramaswamy cites campaign to duck deposition in buyout suit

August 24, 2023 | msn.com

Bill Ackman Tells Vivek Ramaswamy How To Run For President

August 24, 2023 | finance.yahoo.com

Uterine Fibroids Treatment Global Market Report 2023

August 21, 2023 | benzinga.com

Presidential Hopeful Ramaswamy Predicts US Recession In 2024

July 4, 2023 | uk.finance.yahoo.com

Hormone Therapy Global Market Report 2023

June 26, 2023 | finance.yahoo.com

Health in Her HUE to Host Discussion Around Fibroids Awareness and Launch the Fibroids-focused Care Squad Program during Fibroid Awareness Month

June 22, 2023 | benzinga.com

Antibacterial Drugs Market to Reach US$ 62 Billion by 2031 | Fact.MR Report

May 18, 2023 | finance.yahoo.com

Women's Health Market to Reach $63.02 Billion by 2030: Grand View Research, Inc.

May 17, 2023 | finance.yahoo.com

Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids

May 16, 2023 | marketwatch.com

Endometriosis Treatment Drugs Market Top Competitors and Prediction Till 2030

May 10, 2023 | marketwatch.com

Metastatic Prostate Cancer Treatment Market Size: Growth Dynamics from 2023 to 2031

May 8, 2023 | marketwatch.com

Menstrual Cramps Treatment Market worth growing 4.0% at a CAGR by 2027

See More Headlines

Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/26/2021
Today: 4/19/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:MYOV
Previous Symbol: NASDAQ:MYOV
CUSIP: N/A
CIK: 1679082
Web: www.myovant.com
Phone: 442074003351
Fax: N/A
Employees: 407
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-205,980,000.00
Net Margins: -48.47%
Pretax Margin: -42.81%
Return on Equity: N/A
Return on Assets: -39.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.57
Quick Ratio: 1.45

Sales & Book Value

Annual Sales: $230.97 million
Price / Sales: 11.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($5.04) per share
Price / Book: -5.35

Miscellaneous

Outstanding Shares: 97,240,000
Free Float: 95,388,000
Market Cap: $2.62 billion
Optionable: Not Optionable
Beta: 2.17

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

David C. Marek
Chief Executive Officer & Director
Jeffrey D. Nornhold
Senior VP-Pharmaceutical Operations & Development
Uneek Mehra
Chief Financial & Business Officer
Juan Camilo Arjona Ferreira
Chief Medical Officer
Matthew Lang
Secretary, Chief Administrative & Legal Officer

Key Competitors

View All Competitors

MYOV Stock Analysis - Frequently Asked Questions

How were Myovant Sciences' earnings last quarter?: Myovant Sciences Ltd. (NYSE:MYOV) issued its quarterly earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.11. The firm had revenue of $77.90 million for the quarter, compared to the consensus estimate of $72.67 million. During the same quarter in the previous year, the company posted ($0.75) earnings per share.
What other stocks do shareholders of Myovant Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).
When did Myovant Sciences IPO?: Myovant Sciences (MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

This page (NYSE:MYOV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Myovant Sciences (MYOV) Stock Price, News & Analysis

About Myovant Sciences Stock (NYSE:MYOV)

MYOV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

MYOV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info